Current therapy guidelines of heart rhythm disturbances;Herzrhythmusstörungen und deren Therapie entsprechend aktuellen Empfehlungen

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 49, 2010, Pages 2461-2476

  Hammwohner M ^a   Goette, A ^a  

^a St Vincenz Hospital   (Germany)

Author keywords

antiarrhythmic agents; arrhythmia; catheter ablation; defibrillator; heart

Indexed keywords

ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SARTAN DERIVATIVE;

HEART ARRHYTHMIA; HUMAN; PRACTICE GUIDELINE; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MIDDLE AGED;

EID: 78649901971     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1269418     Document Type: Review

References (75)

1. Alboni P, Botto G L., Boriani G et al. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during pill-in-the-pocket treatment. Heart 2010 96 546-549
2. Bardy G H., Lee K L., Mark D B. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 225-237
3. Bellocq C, van Ginneken A C., Bezzina C R. et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004 109 2394-2397
4. Blackshear J L., Safford R E. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card Electrophysiol Rev 2003 7 366-369
5. Blomstrom-Lundqvist C, Scheinman M M., Aliot E M. et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 2003 42 1493-1531
6. Brendorp B, Torp-Pedersen C, Elming H, Kober L. Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy. Eur Heart J 2003 24 274-279
7. Brugada R, Hong K, Dumaine R et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004 109 30-35
8. Camm A J., Kirchhof P, Lip G Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 31 2369-2429
9. Cappato R, Calkins H, Chen S A. et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009 53 1798-1803
10. Cappato R, Calkins H, Chen S A. et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005 111 1100-1105
11. Connolly S J., Gent M, Roberts R S. et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000 101 1297-1302
12. Connolly S J., Hallstrom A P., Cappato R et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000 21 2071-2078
13. Dorian P. Rate control in atrial fibrillation. N Engl J Med 2010 362 1439-1441
14. Duray G Z., Schmitt J, Hohnloser S H. Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials. J Cardiovasc Pharmacol Ther 2010 Epub ahead of print
15. Fuster V, Ryden L E., Cannom D S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 114 e257-e354
16. Gaita F, Giustetto C, Bianchi F et al. Short QT Syndrome: a familial cause of sudden death. Circulation 2003 108 965-970
17. Giustetto C, Di M F., Wolpert C et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006 27 2440-2447
18. Goette A. Möglichkeiten und Grenzen der derzeitigen medikamentösen Behandlung von Vorhofflimmern. Dtsch Med Wochenschr 2010 135 Suppl 2 S33-S37
19. Goette A, Bukowska A, Dobrev D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 2009 30 1411-1420
20. Goette A, Honeycutt C, Langberg J J. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996 94 2968-2974
21. Goldberg A S., Bathina M N., Mickelsen S, Nawman R, West G, Kusumoto F M. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 2002 89 1120-1123
22. Greene H L. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 1993 72 70F-74F
23. Gussak I, Wright R S., Kopecky S L., Hammill S C. Exercise-induced ST segment elevation in Q wave leads in postinfarction patients: defining its meaning and utility in todays practice. Cardiology 2000 93 205-209
24. Haissaguerre M, Warin J F., Lemetayer P, Saoudi N, Guillem J P., Blanchot P. Closed-chest ablation of retrograde conduction in patients with atrioventricular nodal reentrant tachycardia. N Engl J Med 1989 320 426-433
25. Hammwöhner M, Goette A. Will Warfarin soon be passe? New approaches to stroke prevention in atrial fibrillation. J Cardiovasc Pharmacol 2008 52 18-27
26. Haverkamp W. Kongenitales Long-QT-Syndrom. Herz 2007 32 201-205
27. Hohnloser S H., Crijns H J., EM et al. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J 2010 31 1717-1721
28. Hsu L F., Jais P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 351 2373-2383
29. Jackman W M., Beckman K J., McClelland J H. et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 1992 327 313-318
30. Jais P, Hocini M, Hsu L F. et al. Technique and results of linear ablation at the mitral isthmus. Circulation 2004 110 2996-3002
31. Khan M N., Jais P, Cummings J et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008 359 1778-1785
32. Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference research perspectives in AF. Eur Heart J 2009 30 2969-77c
33. Kontula K, Laitinen P J., Lehtonen A, Toivonen L, Viitasalo M, Swan H. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc Res 2005 67 379-387
34. Kuck K H., Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000 102 748-754
35. Kuck K H., Ernst S, Dorwarth U et al. Leitlinien zur Kathe. Clin Res Cardiol 2007 96 833-849
36. Kuck K H., Schaumann A, Eckardt L et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010 375 31-40
37. Lafuente-Lafuente C, Mouly S, Longas-Tejero M A., Bergmann J F. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007 CD005049
38. Lafuente-Lafuente C, Mouly S, Longas-Tejero M A., Mahe I, Bergmann J F. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006 166 719-728
39. Lai L P., Su M J., Lin J L. et al. Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 1999 33 1231-1237
40. Marian A J. Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J 2009 36 194-204
41. Marian A J. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010 40 360-369
42. Mason J W. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993 329 445-451
43. Mason J W. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993 329 452-458
44. Moss A J., Zareba W, Benhorin J et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995 92 2929-2934
45. Moss A J., Zareba W, Hall W J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 346 877-883
46. Moss A J., Zareba W, Hall W J. et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000 101 616-623
47. Nademanee K, McKenzie J, Kosar E et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004 43 2044-2053
48. Natale A, Newby K H., Pisano E et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 2000 35 1898-1904
49. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002 415 219-226
50. Ouyang F, Bansch D, Ernst S et al. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004 110 2090-2096
51. Pedersen O D., Brendorp B, Kober L, Torp-Pedersen C. Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF study. Congest Heart Fail 2003 9 333-340
52. Priori S G., Barhanin J, Hauer R N. et al. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J 1999 20 174-195
53. Priori S G., Pandit S V., Rivolta I et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005 96 800-807
54. Rautaharju P M., Zhou S H., Wong S et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992 8 690-695
55. Reddy V Y., Reynolds M R., Neuzil P et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007 357 2657-2665
56. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000 342 913-920
57. Schauerte P, Scherlag B J., Pitha J et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000 102 2774-2780
58. Scheinman M M. NASPE Survey on Catheter Ablation. Pacing Clin Electrophysiol 1995 18 1474-1478
59. Schilling R J. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart 2010 96 333-338
60. Schimpf R, Bauersfeld U, Gaita F, Wolpert C. Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm 2005 2 416-417
61. Schulze-Bahr E, Breithardt G. Short QT interval and short QT syndromes. J Cardiovasc Electrophysiol 2005 16 397-398
62. Shlofmitz R A., Hirsch B E., Meyer B R. New-onset atrial fibrillation: is there need for emergent hospitalization? J Gen Intern Med 1986 1 139-142
63. Singh S N., Singh B N., Reda D J. et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 2003 92 468-472
64. Steven D, Lutomsky B, Rostock T, Willems S. Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen. Ein Update zur konventionellen Therapie. Internist (Berl) 2006 47 1013-20, 1022
65. Tome Esteban M T., Garcia-Pinilla J M., McKenna W J. [Update in arrhythmogenic right ventricular cardiomyopathy: genetic, clinical presentation and risk stratification]. Rev Esp Cardiol 2004 57 757-767
66. Van Gelder I C., Groenveld H F., Crijns H J. et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010 362 1363-1373
67. Van Gelder I C., Hagens V E., Bosker H A. et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 1834-1840
68. Van Wagoner D R. Electrophysiological remodeling in human atrial fibrillation. Pacing Clin Electrophysiol 2003 26 1572-1575
69. Wanless R S., Anderson K, Joy M, Joseph S P. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997 133 441-446
70. Wittkowsky A K. The pill-in-the-pocket approach to atrial fibrillation. N Engl J Med 2005 352 1150-1151
71. Wolf P A., Dawber T R., Thomas Jr H E., Kannel W B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978 28 973-977
72. Wolpert C, Schimpf R, Veltmann C, Borggrefe M. Kurzes QT-Syndrom. Herz 2007 32 206-210
73. Wyse D G., Waldo A L., DiMarco J P. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 1825-1833
74. Ylanen K, Poutanen T, Hiippala A, Swan H, Korppi M. Catecholaminergic polymorphic ventricular tachycardia. Eur J Pediatr 2010 169 535-542
75. Zipes D P., Camm A J., Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006 8 746-837